STOCKHOLDERS AGREEMENT by and among CHIESI FARMACEUTICI SPA, CRAIG A. COLLARD, STEVEN M. LUTZ, CORNERSTONE BIOPHARMA HOLDINGS, LTD., CAROLINA PHARMACEUTICALS, LTD., LUTZ FAMILY LIMITED PARTNERSHIP and CORNERSTONE THERAPEUTICS INC. Dated as of May 6, 2009
Exhibit 10.4
by and among
CHIESI FARMACEUTICI SPA,
XXXXX X. XXXXXXX,
XXXXXX X. XXXX,
CORNERSTONE BIOPHARMA HOLDINGS, LTD.,
CAROLINA PHARMACEUTICALS, LTD.,
XXXX FAMILY LIMITED PARTNERSHIP
and
Dated as of May 6, 2009
TABLE OF CONTENTS
| Page | ||||
ARTICLE I DEFINITIONS |
1 | |||
Section 1.1. Defined Terms |
1 | |||
ARTICLE II REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS |
3 | |||
Section 2.1. Ownership of Shares |
3 | |||
Section 2.2. Authority |
3 | |||
Section 2.3. Consents and Approvals; No Violations |
3 | |||
ARTICLE III LIQUIDITY AND TRANSFER RESTRICTIONS |
4 | |||
Section 3.1. Ownership of Shares; Legend |
4 | |||
Section 3.2. Limitations on Transfers of Common Stock During the Blackout Period |
5 | |||
Section 3.3. Purchaser’s Call Option |
5 | |||
Section 3.4. Limitations on Purchases of Additional Common Stock |
6 | |||
ARTICLE IV VOTING |
6 | |||
Section 4.1. Agreement to Vote |
6 | |||
ARTICLE V MISCELLANEOUS |
7 | |||
Section 5.1. Further Assurances |
7 | |||
Section 5.2. Notices |
7 | |||
Section 5.3. Entire Agreement |
8 | |||
Section 5.4. Waiver |
8 | |||
Section 5.5. Amendment |
9 | |||
Section 5.6. No Third-Party Beneficiaries |
9 | |||
Section 5.7. Assignment; Binding Effect |
9 | |||
Section 5.8. Governing Law |
9 | |||
Section 5.9. CONSENT TO JURISDICTION AND SERVICE OF PROCESS; WAIVER OF JURY TRIAL |
9 | |||
Section 5.10. Remedies |
10 | |||
Section 5.11. Invalid Provisions |
10 | |||
Section 5.12. Counterparts |
10 | |||
Section 5.13. Effectiveness; Termination |
10 | |||
Annex A Covered Shares |
||||
i
This STOCKHOLDERS AGREEMENT, dated as of May 6, 2009 (this “Agreement”), is by and
among CHIESI FARMACEUTICI SPA, a corporation organized under the laws of Italy
(“Purchaser”), XXXXX X. XXXXXXX, CORNERSTONE BIOPHARMA HOLDINGS, LTD., a limited liability
company organized under the laws of Anguilla, CAROLINA PHARMACEUTICALS, LTD., a limited liability
company organized under the laws of Bermuda, XXXX FAMILY LIMITED PARTNERSHIP, North Carolina
limited partnership, and XXXXXX X. XXXX (the “Stockholders”), and CORNERSTONE THERAPEUTICS
INC., a Delaware corporation (the “Company”).
RECITALS
WHEREAS, concurrently with the execution and delivery of this Agreement, (i) Purchaser and
certain of the Stockholders are entering into a Stock Purchase Agreement (the “Initial Stock
Purchase Agreement”), dated the same date as this Agreement, and (ii) the Company and Purchaser
are entering into a Stock Purchase Agreement (the “Company Stock Purchase Agreement”), also
dated the same date as this Agreement;
WHEREAS, following consummation of the transactions contemplated by the Initial Stock Purchase
Agreement and the Company Stock Purchase Agreement, Purchaser will own approximately 13,502,741
shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”); and
WHEREAS, the parties to this Agreement desire to set forth certain agreements regarding future
transfers of Common Stock by any of the Stockholders, and regarding an option on the part of
Purchaser to purchase certain shares of Common Stock from the Stockholders;
NOW, THEREFORE, the parties hereto hereby agree as follows:
ARTICLE I
DEFINITIONS
Section 1.1. Defined Terms. As used in this Agreement, the following terms shall have
the respective meanings set forth below:
“Beneficially Own” shall mean, with respect to any security, having the power to
direct or control the voting or disposition of such security, and “Beneficially Owned”
shall have a correlative meaning. For this purpose, securities underlying an immediately
exercisable option or conversion or similar right are deemed Beneficially Owned by the holder of
the option or other such right.
“Beneficial Owner” shall mean, with respect to any security, a Person who Beneficially
Owns such security, and “Beneficial Ownership” shall have a correlative meaning.
“Blackout Period” shall mean the period beginning on the Closing and ending at
11:59 p.m. New York City time on the second anniversary of the Closing.
“Business Day” shall mean any day other than a Saturday, Sunday or other day on which
commercial banks located in New York City, New York are required or permitted by law to be closed
for the conduct of regular banking business.
“Call Option Period” shall mean as to any Stockholder the period beginning at
9:00 a.m. New York City time on the earlier to occur of the (i) the expiration of the Blackout
Period and (ii) the date following the date of the Employment Termination Event and ending on the
date that is 30 days after such date.
“Closing” shall mean the Closing provided for in the Company Stock Purchase Agreement.
“Corporate Affiliate” shall mean, with respect to any Stockholder, a corporation of
which all the capital stock is owned, directly or indirectly, by such Stockholder.
“Covered Shares” shall mean, with respect to each Stockholder, the number of shares of
Common Stock set forth opposite the name of such Stockholder on Annex A under “Covered
Shares”, ratably and equitably adjusted to take into account any stock split, stock dividend,
reverse stock split or similar adjustment to capital stock occurring after the date of this
Agreement.
“Employment Termination Event” shall mean (i) as to Xxxxx X. Xxxxxxx, Cornerstone
Biopharma Holdings, Ltd. and Carolina Pharmaceuticals, Ltd. the date of termination of Xx.
Xxxxxxx’x employment with the Company and (ii) as to Xxxxxx X. Xxxx and Xxxx Family Limited
Partnership the date of termination of Xx. Xxxx’x employment with the Company; provided,
that in each such case, a termination that results from a resignation without Good Reason and
termination for Cause (as those terms are defined in the applicable employment agreements with the
Company) shall not constitute an Employment Termination Event.
“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.
“Exempt Transfer” shall mean any direct or indirect Transfer of Beneficial Ownership
of Common Stock made:
| (i) | to any Trust Affiliate, Partnership Affiliate or Corporate Affiliate of the transferor; provided, that after giving effect to such Transfer, the transferor continues to own at least one share of Common Stock and continues to be a party to this Agreement and bound by the terms and provisions hereof; and further provided, that if on a later date the condition in the foregoing proviso ceases to be satisfied or such Trust Affiliate, Partnership Affiliate or Corporate Affiliate ceases to be a Trust Affiliate, Partnership Affiliate or Corporate Affiliate of the transferor, a Transfer (which shall not constitute an Exempt Transfer) of the amount of Common Stock originally Transferred to such transferee shall be deemed to have occurred; or | ||
| (ii) | by operation of the laws of descent and distribution. |
“Partnership Affiliate” shall mean, with respect to any Stockholder, a limited
partnership, the general partner of which is, or is under the exclusive control of, and the
majority of the limited liability partnership interests of which are owned by, such Stockholder.
“Per Share Option Price” shall mean $12.00, ratably and equitably adjusted to take
into account any stock split, stock dividend, reverse stock split or similar adjustment to capital
stock occurring after the date of this Agreement.
“Person” shall mean any individual, partnership, firm, corporation, association, joint
venture, trust or other entity, or any government or political subdivision or agency, department or
instrumentality thereof.
2
“Transfer” shall mean any sale, assignment or other outright transfer of Beneficial
Ownership of any shares of Common Stock. “Transferred” shall have a correlative meaning.
“Trust Affiliate” shall mean, with respect to any Stockholder, a trust established for
the primary benefit of such Stockholder, so long as the only Persons entitled to direct the voting
of any Common Stock held by the trust are the transferor, another Stockholder, or a bank or other
corporation having trust powers.
In addition, the following terms are defined elsewhere in the Agreement:
“Agreement”
|
Preamble | |
“Call Option
|
Section 3.3(a) | |
“Call Option Closing Date
|
Section 3.3(b) | |
“Call Option Notice”
|
Section 3.3(b) | |
“Company”
|
Preamble | |
“Company Stock Purchase Agreement”
|
Recitals | |
“Common Stock”
|
Recitals | |
“contract”
|
Section 2.3(b) | |
“Encumbrances”
|
Section 2.1 | |
“Governmental Authority”
|
Section 2.3(a) | |
“Purchaser”
|
Preamble | |
“Stockholders”
|
Preamble |
ARTICLE II
REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS
Each Stockholder represents and warrants, severally but not jointly and solely with respect to
such Stockholder and not with respect to the other Stockholder, to Purchaser as follows:
Section 2.1. Ownership of Shares. As of the date of this Agreement, such Stockholder
is the lawful record and beneficial owner of the number of shares of Common Stock set forth next to
such Stockholder’s name on Exhibit A free and clear of all liens, charges, security
interests, mortgages, pledges, options, preemptive rights, rights of first refusal or first offer,
proxies, levies, voting trusts or agreements, or other adverse claims or restrictions on title or
transfer of any nature whatsoever (collectively, “Encumbrances”), other than restrictions
on transfer imposed under applicable securities laws.
Section 2.2. Authority. Such Stockholder is either (a) an individual with the
requisite legal capacity and authority or (b) an entity with the requisite partnership or limited
liability company power and authority to execute and deliver this Agreement and to perform the
transactions contemplated by this Agreement. This Agreement has been duly and validly executed and
delivered by such Stockholder and, assuming the due authorization, execution and delivery of this
Agreement by each other party hereto, constitutes legal, valid and binding obligations of such
Stockholder, enforceable against such Stockholder in accordance with its terms.
Section 2.3. Consents and Approvals; No Violations.
(a) The execution, delivery and performance by such Stockholder of this Agreement and the
consummation by such Stockholder of the transactions contemplated hereby do not and will not
require any filing or registration with, notification to, or authorization, permit, consent or
approval of, or other action
3
by or in respect of, any U.S. or non-U.S. government, regulatory or administrative authority,
agency, instrumentality or commission or any court, tribunal, judicial or arbitral body or other
similar authority (a “Governmental Authority”) other than where the failure to obtain such
consents, approvals, authorizations or permits or to make such filings or notifications would not
reasonably be expected to have a Material Adverse Effect (as defined in the Company Stock Purchase
Agreement).
(b) The execution, delivery and performance by such Stockholder of this Agreement and the
consummation by such Stockholder of the transactions contemplated hereby do not and will not (i)
result in a violation or breach of, or constitute (with or without notice or lapse of time or both)
a default under, or give rise to any right of termination, amendment, cancellation, acceleration or
loss of benefits or the creation or acceleration of any right or obligation under or result in the
creation of any Encumbrance upon any of the properties or assets of such Stockholder under, any of
the terms, conditions or provisions of any note, bond, mortgage, indenture, deed of trust, loan,
credit agreement, lease, license, permit, concession, franchise, purchase order, sales order,
contract, agreement or other instrument, understanding or obligation, whether written or oral (a
“contract”), to which such Stockholder is a party or by which any of its properties or
assets may be bound or (ii) violate any law applicable to such Stockholder or any of his properties
or assets, except in each such case as would not reasonably be expected to prevent or delay the
consummation of the transactions contemplated hereby.
ARTICLE III
LIQUIDITY AND TRANSFER RESTRICTIONS
Section 3.1. Ownership of Shares; Legend.
(a) Each certificate representing any of the shares of Common Stock held by a Stockholder
shall bear the following legend in addition to any other legend required under applicable law:
THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE
TERMS AND CONDITIONS OF A STOCKHOLDERS AGREEMENT BY AND AMONG THE
COMPANY AND THE PERSONS SPECIFIED THEREIN, A COPY OF WHICH AGREEMENT
IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. THE SALE,
TRANSFER OR OTHER DISPOSITION OF THE SECURITIES IS SUBJECT TO THE
TERMS OF SUCH AGREEMENT AND THE SECURITIES ARE TRANSFERABLE ONLY
UPON PROOF OF COMPLIANCE THEREWITH.
(b) A notation will be made in the appropriate transfer records of the Company with respect
to the restrictions on Transfer of the shares of Common Stock referred to in this Agreement.
(c) It shall be a condition precedent to any Exempt Transfer of shares of Common Stock to
any Person who is not a party to this Agreement that such Person agree in writing to be bound by
the obligations of such Person’s transferor under this Agreement and for all purposes thereafter
the definition of Stockholder as used in this Agreement shall include transferees. If the
transferee acquires its shares pursuant to an Exempt Transfer, upon consummation of such Exempt
Transfer in accordance with this Agreement the transferee will succeed to the rights of the
transferor under this Agreement.
4
Section 3.2. Limitations on Transfers of Common Stock During the Blackout Period.
(a) During the Blackout Period, no Stockholder shall, directly or indirectly, Transfer any
Covered Shares except (i) pursuant to an Exempt Transfer or (ii) as permitted or required
pursuant to any other provision of this Article III.
(b) During the Blackout Period, no Stockholder shall knowingly Transfer any shares of
Common Stock in a privately negotiated transaction to a pharmaceutical company.
(c) Following the Blackout Period, there shall be no further restriction on Transfers of
Shares of Common Stock by any Stockholder. Any Transfer or purported Transfer in violation of
the foregoing restrictions shall be void and of no effect and shall not be recognized by the
Company.
Section 3.3. Purchaser’s Call Option.
(a) Purchaser shall have an option (the “Call Option”), exercisable in whole but
not in part on a single occasion during the Call Option Period applicable to any Stockholder and
such Stockholder’s affiliates, to acquire all the Covered Shares then owned by such Stockholder
and such Stockholder’s affiliates, for a price per Covered Share equal to the Per Share Option
Price on the terms set forth in this Section 3.3.
(b) The Call Option may be exercised by Purchaser by delivery of a notice (the “Call
Option Notice”) to the Stockholders stating (i) that Purchaser is exercising the Call
Option; and (ii) the date (the “Call Option Closing Date”) on which the sale of Covered
Shares pursuant to the Call Option is to occur (which shall be a Business Day not less than 5
Business Days and not more than 15 Business Days after the later of (x) the date of the Call
Option Notice, or (y) the first date on which all applicable governmental and third party
permits, approvals and notices applicable to the exercise of the Call Option have been given or
obtained, and all legally required waiting periods have expired). Purchaser and the
Stockholders will use reasonable best efforts (and cause the Company to use its reasonable best
efforts) to obtain and give all applicable governmental permits, approvals and notices required
for the exercise of the Call Option as promptly as reasonably practicable.
(c) Delivery of a Call Option Notice shall create a binding obligation on the part of
Purchaser to purchase all the Covered Shares from the recipients of the Call Option Notice for a
purchase price, payable in full in cash at the closing of the sale, equal to the aggregate Per
Share Option Price of the Covered Shares, and a binding obligation on the part of such recipient
to sell those shares for that price. The closing of the purchase and sale of the shares shall
take place at the principal business offices of the Company at 10:00 AM local time on the Call
Option Closing Date. At the closing, each selling Stockholder shall deliver (1) one or more
stock certificates, duly endorsed or with duly executed stock powers attached, conveying the
requisite number of shares to Purchaser or its nominee, duly authorized and validly issued, free
and clear of all Encumbrances (other than restrictions imposed under applicable securities laws
or this Agreement), and (2) a certificate representing that the selling Stockholder is
transferring good and marketable title to such shares (or interests therein) free of all such
Encumbrances. Purchaser shall pay the applicable purchase price to each selling Stockholder at
the closing against delivery of the stock certificates by certified or bank check or, if
requested by the selling Stockholder, by wire transfer of immediately available funds to an
account specified by the selling Stockholder.
(d) If any Covered Shares in respect of which a Call Option is exercised are Beneficially
Owned pursuant to an unexercised but immediately exercisable stock option, so long as the Per
Share Option Price is greater than the exercise price per share of the option, then at or prior
to the applicable Call Option Closing Date, the applicable selling Stockholder shall exercise
such option in accordance with the applicable stock option plan and stock option agreement
governing such stock option and the
5
Purchaser shall purchase such underlying shares for delivery at the closing of the Call
Option exercise. Any purported exercise of the Call Option with respect to Covered Shares that
are subject to a stock option shall be invalid unless the Per Share Option Price is at least
equal to the exercise price per share of the option and the stock option is immediately
exerciseable.
Section 3.4. Limitations on Purchases of Additional Common Stock. Each Stockholder
agrees that, during the Blackout Period, such Stockholder shall not, directly or indirectly,
purchase or otherwise acquire, or propose or offer to purchase or acquire, any shares of Common
Stock or any Beneficial Ownership thereof, whether by tender offer, market purchase, privately
negotiated purchase, merger or otherwise, except through acquisitions of shares of Common Stock (i)
effected pursuant to transactions approved by the Company’s board of directors or by a majority of
the independent directors on the Company’s board of directors; (ii) effected solely to the extent
necessary to maintain the Stockholder’s level of Beneficial Ownership of the shares of Common Stock
as of the date hereof; and (iii) pursuant to the Company’s equity compensation arrangements or the
exercise of any options or warrants or similar rights granted or awarded under such arrangements.
ARTICLE IV
VOTING
Section 4.1. Agreement to Vote. Each Stockholder agrees that, at any meeting of the
stockholders of the Company called to consider a transaction in which Purchaser or its affiliate
will acquire all the outstanding capital stock of the Company, such Stockholder shall vote all
shares of Common Stock owned by such Stockholder at the applicable record date set for such meeting
in the same proportions that the shares of Common Stock Beneficially Owned by the other
stockholders of the Company (other than Purchaser and its affiliates) are voted on such matter.
The Stockholders’ obligations under this Section 4.1 shall apply only if (i) the directors
of the Company who were not designated by, and are otherwise independent of, Purchaser and its
affiliates (other than the Company) shall have approved the transaction to be voted on at the
meeting, and shall have recommended that the Company’s stockholders vote to approve the
transaction, by the affirmative vote of a majority of such directors; and (ii) such approval and
recommendation shall not have been withdrawn.
6
ARTICLE V
MISCELLANEOUS
Section 5.1. Further Assurances. Each party shall execute and deliver such additional
instruments and other documents and shall take such further actions as may be necessary or
appropriate to effectuate, carry out and comply with all of the terms of this Agreement and the
transactions contemplated hereby, including making application for all consents and approvals
required in connection with the transactions contemplated hereby and diligently pursuing the
receipt of such consents and approvals in good faith thereafter at such time as may be necessary to
comply with all of the terms of this Agreement and the transactions contemplated hereby.
Section 5.2. Notices.
(a) All notices and other communications under this Agreement must be in writing and
delivered to the applicable party or parties in person or by delivery to the address or
facsimile number specified below (or to such other address or facsimile number as the recipient
previously shall have specified by notice to the other parties hereunder):
If to Purchaser:
Chiesi Farmaceutici SpA
Xxx Xxxxxxx 00/X
00000 Xxxxx
Xxxxx
Attention: President
Copy to: Head of Corporate Development and Legal and
Corporate Affairs Director
Facsimile: x00 0000 000000
Xxx Xxxxxxx 00/X
00000 Xxxxx
Xxxxx
Attention: President
Copy to: Head of Corporate Development and Legal and
Corporate Affairs Director
Facsimile: x00 0000 000000
with copies to:
Xxxxxx, Xxxxx & Xxxxxxx LLP
0000 Xxxxxxxxxxxx Xxxxxx, XX
Xxxxxxxxxx, XX 00000
Attention: Xxxxxxx Xxxx Xxxxxxx
Facsimile: (000) 000-0000
0000 Xxxxxxxxxxxx Xxxxxx, XX
Xxxxxxxxxx, XX 00000
Attention: Xxxxxxx Xxxx Xxxxxxx
Facsimile: (000) 000-0000
and
7
Xxxxxx, Xxxxx & Xxxxxxx LLP
000 Xxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Attention: Xxxxxx Xxxxxx and Xxxxxx Xxxxxxx
Facsimile: (000) 000-0000
000 Xxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Attention: Xxxxxx Xxxxxx and Xxxxxx Xxxxxxx
Facsimile: (000) 000-0000
If to the Stockholders:
c/o Cornerstone Therapeutics Inc.
0000 Xxxxxxxx Xxxxx Xxxxx, Xxxxx 000
Xxxx, XX 00000
Attention: Chief Financial Officer
Copy to: General Counsel
Facsimile: (000) 000-0000
0000 Xxxxxxxx Xxxxx Xxxxx, Xxxxx 000
Xxxx, XX 00000
Attention: Chief Financial Officer
Copy to: General Counsel
Facsimile: (000) 000-0000
If to the Company:
c/o Cornerstone Therapeutics Inc.
0000 Xxxxxxxx Xxxxx Xxxxx, Xxxxx 000
Xxxx, XX 00000
Attention: Chief Financial Officer
Copy to: General Counsel
Facsimile: (000) 000-0000
0000 Xxxxxxxx Xxxxx Xxxxx, Xxxxx 000
Xxxx, XX 00000
Attention: Chief Financial Officer
Copy to: General Counsel
Facsimile: (000) 000-0000
with a copy to:
Xxxxxxxx Chance US LLP
00 Xxxx 00xx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Attention: Xxxx X. Xxxxx
Facsimile: (000) 000-0000
00 Xxxx 00xx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Attention: Xxxx X. Xxxxx
Facsimile: (000) 000-0000
(b) All notices and other communications sent to the applicable address or facsimile number
specified above shall be deemed to have been delivered at the earlier of (i) the time of actual
receipt by the addressee; (ii) if the notice is sent by facsimile transmission, the time indicated
on the transmitting party’s receipt of confirmation of transmission that time is during the
addressee’s regular business hours on a Business Day, and otherwise at 9:00 a.m. on the next
Business Day after such time; and (iii) if the notice is sent by a nationally recognized, reputable
overnight courier service, the time shown on the confirmation of delivery provided by that service
if that time is during the recipient’s regular business hours on a Business Day, and otherwise at
9:00 a.m. on the next Business Day after such time.
Section 5.3. Entire Agreement. This Agreement and the exhibits, annexes and schedules
hereto, constitute the sole and entire agreement among the parties to this Agreement with respect
to the subject matter of this Agreement, and supersede all prior and contemporaneous
representations, agreements and understandings, written or oral, with respect to the subject matter
hereof.
Section 5.4. Waiver. Subject to applicable law and except as otherwise provided in
this Agreement, any party to this Agreement may, at any time prior to the Closing, extend the time
for performance of any obligation under this Agreement of any other party or waive compliance with
any term or condition of this Agreement by any other party. No such extension or waiver shall be
effective
8
unless set forth in a written instrument duly executed by the party granting such extension or
waiver. No delay in asserting or exercising a right under this Agreement shall be deemed a wavier
of that right.
Section 5.5. Amendment. Subject to applicable law and except as otherwise provided in
this Agreement, this Agreement may be amended, supplemented or modified at any time;
provided, that no such amendment, supplement or modification shall be effective unless it
is set forth in a written instrument duly executed by the Company, Purchaser and by each
Stockholder whose rights or obligations are altered thereby.
Section 5.6. No Third-Party Beneficiaries. The terms and provisions of this Agreement
are intended solely for the benefit of each party hereto and their respective successors or
permitted assigns, and it is not the intention of the parties to confer third-party beneficiary
rights upon any other person.
Section 5.7. Assignment; Binding Effect. Except as otherwise expressly provided; this
Agreement, neither this Agreement nor any right, interest or obligation under this Agreement may be
assigned by any party to this Agreement, by operation of law or otherwise, without the prior
written consent of the other parties to this Agreement and any attempt to do so will be void.
Subject to the foregoing, this Agreement is binding upon, inures to the benefit of and is
enforceable by the parties to this Agreement and their respective successors and assigns.
Section 5.8. Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD FOR ANY OF THE CONFLICTS OF LAWS
PRINCIPLES THEREOF THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION.
Section 5.9. CONSENT TO JURISDICTION AND SERVICE OF PROCESS; WAIVER OF JURY TRIAL.
EACH PARTY TO THIS AGREEMENT HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE
DELAWARE CHANCERY COURT SITTING IN THE COUNTY OF NEW CASTLE, OR IF SUCH COURT SHALL NOT HAVE PROPER
JURISDICTION, OF THE UNITED STATES FEDERAL DISTRICT COURT SITTING IN DELAWARE, AND ANY APPELLATE
COURT THEREOF, IN RESPECT OF ANY ACTION, SUIT OR PROCEEDING ARISING OUT OF OR IN CONNECTION WITH
THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, AND AGREES THAT ANY SUCH ACTION, SUIT OR
PROCEEDING SHALL BE BROUGHT ONLY IN SUCH COURTS (AND WAIVES AND AGREES NOT TO ASSERT ANY OBJECTION
BASED ON FORUM NON CONVENIENS OR ANY OTHER OBJECTION TO VENUE THEREIN OR JURISDICTION THEREOF);
PROVIDED, HOWEVER, THAT SUCH CONSENT TO JURISDICTION IS SOLELY FOR THE PURPOSE REFERRED TO IN THIS
SECTION 5.9 AND SHALL NOT BE DEEMED TO BE A GENERAL SUBMISSION TO THE JURISDICTION OF SAID
COURTS OR IN THE STATE OF DELAWARE OTHER THAN FOR SUCH PURPOSE. Any and all process may be served
in any action, suit or proceeding arising in connection with this Agreement by complying with the
provisions of Section 5.2. Such service of process shall have the same effect as if the
party being served were a resident in the State of Delaware and had been lawfully served with such
process in such jurisdiction. The parties hereby waive all claims of error by reason of such
service. Nothing herein shall affect the right of any party to serve process in any other manner
permitted by law or to commence legal proceedings or otherwise proceed against the other in any
other jurisdiction to enforce judgments or rulings of the aforementioned courts. EACH PARTY TO
THIS AGREEMENT HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY
HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER
OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH OF THE PARTIES
9
HERETO (A) CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR
OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE
FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO
ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY, AS APPLICABLE, BY, AMONG OTHER
THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 5.9.
Section 5.10. Remedies. The parties hereto agree that if any of the provisions of
this Agreement were not performed in accordance with their specific terms or were otherwise
breached, irreparable damage would occur, no adequate remedy at law would exist and damages would
be difficult to determine, and that the parties shall be entitled to injunctive relief to prevent
breaches of this Agreement and to specific performance of the terms hereof, in addition to any
other remedy at law or equity to which the parties may be entitled. Except as otherwise provided
herein, all remedies available under this Agreement, at law or otherwise, shall be deemed
cumulative and not alternative or exclusive of other remedies. The exercise by any party of a
particular remedy shall not preclude the exercise of any other remedy.
Section 5.11. Invalid Provisions. If any provision of this Agreement is held to be
illegal, invalid or unenforceable under any present or future law, (a) such provision will be fully
severable, (b) this Agreement will be construed and enforced as if such illegal, invalid or
unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this
Agreement will remain in full force and effect and will not be affected by the illegal, invalid or
unenforceable provision or by its severance herefrom and (d) in lieu of such illegal, invalid or
unenforceable provision, there will be added automatically as a part of this Agreement a legal,
valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable
provision as may be possible and the parties hereto shall cooperate in good faith to formulate and
implement such provision.
Section 5.12. Counterparts. This Agreement may be executed manually or by facsimile,
in any number of counterparts, all of which will constitute one and the same instrument, and will
become effective when a counterpart shall have been executed an delivered by each party to the
other parties (except that parties that are affiliates need not deliver counterparts to each other
in order for this Agreement to be effective).
Section 5.13. Effectiveness; Termination. This Agreement shall become effective as of
the Closing Date (as defined in the Stock Purchase Agreement, dated the same date as this
Agreement, among the Company and Purchaser). Notwithstanding the foregoing, this Agreement shall
terminate automatically, without action of any of the Stockholders, Purchaser or the Company, if
the Company Stock Purchase Agreement is terminated pursuant to Section 6.1 thereof. This
Agreement may be terminated at any time by an instrument in writing signed by all of the parties
hereto and shall terminate automatically as to the relevant Stockholders upon an Employment
Termination Event and as to all parties when the Common Stock is no longer registered under Section
12 of the Exchange Act.
10
IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above.
| CORNERSTONE THERAPEUTICS INC. |
||||
| By: | /s/ Xxxxx X. Xxxxxxx | |||
| Name: | Xxxxx X. Xxxxxxx | |||
| Title: | CEO | |||
| CHIESI FARMACEUTICI SPA |
||||
| By: | /s/ Xxxxxxx Xxxxxx | |||
| Name: | Xxxxxxx Xxxxxx | |||
| Title: | President | |||
[Signature Page to Stockholders Agreement]
| /s/ Xxxxx X. Xxxxxxx | ||||||
| Xxxxx X. Xxxxxxx | ||||||
| CORNERSTONE BIOPHARMA HOLDINGS, LTD. | ||||||
| By: | /s/ Xxxxx X. Xxxxxxx | |||||
| Name: | Xxxxx X. Xxxxxxx | |||||
| Title: | CEO | |||||
| CAROLINA PHARMACEUTICALS LTD. | ||||||
| By: | /s/ Xxxxx X. Xxxxxxx | |||||
| Name: | Xxxxx X. Xxxxxxx | |||||
| Title: | Director | |||||
[Signature Page to Stockholders Agreement]
| /s/ Xxxxxx X. Xxxx | ||||
| Xxxxxx X. Xxxx | ||||
| XXXX FAMILY LIMITED PARTNERSHIP | ||||
| By: XXXXXX X. XXXX, its general partner | ||||
| /s/ Xxxxxx X. Xxxx | ||||
| Xxxxxx X. Xxxx |
[Signature Page to Stockholders Agreement]
ANNEX A
COVERED SHARES
COVERED SHARES
| Stockholder | Number of Covered Shares | |||
Xxxxx Xxxxxxx |
228,559 | |||
Cornerstone Biopharma Holdings, Ltd. |
2,561,780 | |||
Carolina Pharmaceuticals Ltd. |
947,207 | |||
Xxxx Family Limited Partnership |
541,878 | |||
Xxxxxx X. Xxxx |
195,227 | |||
